Lee Hood, Clayton Lewis, Nathan Price, and more
Institute for Systems Biology spinout Arivale has announced its management team and scientific advisory board.
Clayton Lewis is the company's CEO and one of its co-founders. He is also a general partner at Maveron, an Arivale investor. Lee Hood, president of ISB, and Nathan Price, associate director of ISB, are the other company co-founders. Jennifer Lovejoy is Arivale's chief translational science officer. Most recently, she was senior vice president of clinical and quality support at Alere Wellbeing. Sean Bell serves as the company's chief business officer. Previously, he was executive vice president at Free & Clear, a health coaching company.
Arivale's SAB members are chairman Lee Hood, Frances Arnold of the California Institute of Technology, George Church of Harvard Medical School, Robert Green of Brigham and Women's Hospital and Harvard Medical School, Jim Heath of the California Institute of Technology, Ed Lazowska of the University of Washington, Larry Smarr of the University of California San Diego, Ralph Snyderman of Duke University, Bonnie Spring of Northwestern University, and Eric Topol of the Scripps Research Institute.
Gregory Critchfield
Epic Sciences has appointed Sera Prognostics President and CEO Gregory Critchfield to its board. He has more than 30 years of experience in the clinical pathology and diagnostics space and was the former president of Myriad Genetics. Prior to that, Critchfield was chief medical and science officer for Quest Diagnostics. He currently is also on the boards of Integrated Diagnostics, Nodality, and Metamark Genetics.
Alan Schafer
14M Genomics appointed Alan Schafer its CEO. He was previously CEO of Population Genetics Technologies, and before that he was the director of science funding at Wellcome Trust. Prior to that, Schafer was global vice president of technology development at GlaxoSmithKline, and was a co-founder of Hexagen.
Philip Ginsburg
MDxHealth appointed Philip Ginsburg its chief medical officer. In his new role, he will be responsible for the firm's overall clinical strategy, including scientific and clinical affairs. Ginsburg has more than 20 years of experience in commercial medical laboratory and urology and was CMO at Toma Biosciences and Iris International, as well as president of Arista, the personalized medicine division of Iris, which was acquired by Beckman Coulter. He was also a co-founder, CEO and CMO of AlliedPath and served as senior medical director at Gen-Probe and medical director at Quest Diagnostics.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.